xCures announces real world biomarker study for patients with FGFR-mutant bladder cancer receiving Balversa®

Tyra Biosciences supported study investigates if non-invasive blood and urine samples provide biomarkers to assess clinical response to erdafitinib treatment Today, xCures announced their collaboration with Tyra Biosciences for a real-world biomarker study involving patients with FGFR-mutant bladder cancer receiving Balversa® (erdafitinib) as their standard of care medical therapy. The… Read more »

xCures and BioSpark partner to boost Real World Oncology Data offerings

New partnership allows for a 40,000+ patient dataset to unlock new insights into cancer treatments and outcomes. xCures, Inc. and BioSpark, Inc. are proud to announce their strategic partnership to harmonize and commercialize a joint oncology Real World Data (RWD) offering. The partnership unlocks new insights into the treatment and… Read more »

xCures hosts xDECIDE webinars

xCures is inviting the oncology community to register for a 25-minute webinar introducing a new clinical decision support tool: xDECIDE.  Oncology providers now have access to a toolkit that offers tailored recommendations for treatment options and personalized patient health summaries.  To accompany the launch of the platform, Dr. Juneja discusses… Read more »

Jaime Leandro Foundation treats first cancer patient with personalized neoantigen peptide vaccine under expanded access through xCures

First-of-its-kind consortium enables cancer patients to receive anticancer vaccine therapy through compassionate use. The Jaime Leandro Foundation for Therapeutic Cancer Vaccines (JLF) and partners announce the treatment of the first cancer patient with a personalized neoantigen vaccine through a self-pay compassionate use program. JLF is a 501(c)3 non-profit organization whose… Read more »